Starling Oncology, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Starling Oncology, Inc. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $11.30M.
- Starling Oncology, Inc. stock issued during period, value, new issues for the quarter ending 2025-03-31 was $15.36M.
- Starling Oncology, Inc. stock issued during period, value, new issues for the quarter ending 2021-03-31 was $20.00M, a 91.04% decline year-over-year.
- Starling Oncology, Inc. stock issued during period, value, new issues for the quarter ending 2020-03-31 was $223.27M.
- Starling Oncology, Inc. stock issued during period, value, new issues for fiscal 2025 was $13.84M.
- Starling Oncology, Inc. stock issued during period, value, new issues for fiscal 2021 was $46.10M, a 79.35% decline from fiscal 2020.
- Starling Oncology, Inc. stock issued during period, value, new issues for fiscal 2020 was $223.27M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-12-31 | $13.84M 10-K · filed 2026-03-12 | |
| 2025-09-30 | $11.30M 10-Q · filed 2025-11-13 | |
| 2025-03-31 | $15.36M 10-Q · filed 2026-08-06 | |
| 2021-12-31 | $46.10M 10-K · filed 2023-03-16 | |
| 2021-03-31 | $20.00M 10-Q · filed 2022-11-09 | |
| 2020-12-31 | $223.27M 10-K/A · filed 2021-05-24 | |
| 2020-03-31 | $223.27M 10-Q · filed 2021-08-16 |